Roche Holdings entered into a definitive agreement  with Ignyta Inc. (NASDAQ: RXDX) to acquire the biotech company specialized in the oncology field. Under the agreement, Roche agreed to purchase Ignyta at a price of $27.00 per share in cash. I..

Halozyme Therapeutics, Inc. (NASDAQ: HALO) stock up more than 18% on Thursday after the biotechnology company announced that it has licensed its ENHANZE® drug-delivery technology to Roche for exclusive development of an undisclosed therapeutic t..